Psilocybin and psychedelic-assisted therapy: all studies

Page 26 of 26: studies 251 to 252 of 252, newest first. Back to the psilocybin and psychedelic-assisted therapy overview

Research

Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.

American Journal of Therapeutics Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. 14 citations

The primary psychoactive drug in magic mushrooms, psilocybin, induces profound alterations in consciousness through the 5-HT2A receptor. This review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. Despite initial concerns that psilocybin could cause psychosis, contemporary research has demonstrated that psilocybin is...

DOI: 10.1097/mjt.0000000000001724 Full text Mental health treatment Clinical trials Psychedelics Psilocybin therapy +1

A Two-Threshold Model of Psilocybin Response Explains Variability in Psychedelic-Assisted Therapy for Treatment-Resistant Depression

Jesús Isaac Castillo-Sánchez preprint

Abstract The COMP006 Phase 3 trial showed that 39% of patients with treatment-resistant depression (TRD) respond to a single 25 mg dose of psilocybin, while 61% do not — at identical dose, protocol, and pharmacological exposure. No mechanistic explanation for this heterogeneity has been established. Here we propose and validate a two-threshold model in which the psilocybin dose-response...

DOI: 10.21203/rs.3.rs-10847377/v1